摘要
凝血因子Ⅷ蛋白(FⅧ)作为一种凝血替代因子,几十年来一直被用作治疗和预防血友病A(甲型血友病),包括防血友病A患者的异常出血和因该病导致的关节功能异常、手术后的异常大出血等。在以往的研究中,FⅧ是内源性凝血途径中一种重要的凝血因子,其作为凝血因子Ⅸa的辅因子,参与凝血因子Ⅹ的激活并形成内源性凝血途径。本文通过对FⅧ治疗血友病A的阐述,旨在阐明FⅧ在血友病A患者的心血管系统、血管生成和维持骨骼健康等方面所起到的作用。
Coagulation factor_proteinⅧ(FⅧ),as a coagulation replacement factor,has been used to treat and prevent hemophilia A(hemophilia A)for decades.It can prevent hemophilia A patients from bleeding symptoms,joint dysfunction and abnormal massive bleeding after operation caused by the disease.In previous studies,the authors have learned that FⅧwas an important coagulation factor in endogenous coagulation pathway.As a cofactor of coagulation factor IXa,FⅧwas participated in the activation of coagulation factorⅩand form endogenous coagulation pathway.The purpose of this article was to elucidate the role of FⅧin hemophilia A management,including the cardiovascular system,angiogenesis and maintenance of bone health elaborated.
作者
于引航
郝斌
孙权
施慈
YU Yin-hang;HAO Bin;SUN Quan;SHI Ci(Harbin Pacific Biopharmaceutical Co.,Ltd,Harbin 150025,China)
出处
《药物生物技术》
CAS
2020年第5期472-478,共7页
Pharmaceutical Biotechnology
